The purpose of this study was to review the published evidence on the clinical use of nonsteroidal anti-inflammatory drugs (NSAIDs) and to assess the cardiovascular risk (CVR) of cyclooxygenase-2 inhibitors (coxibs), excluding aspirin, by means of a meta-analytic procedure. A search was conducted on MEDLINE and EMBASE databases between October 1999 and June 2018. Cohort and case-control studies showing CVR as relative risk (RR), odds ratio, hazard ratio, or incidence rate ratio associated with NSAIDs versus no treatment were selected. We estimated the pooled RR and the 95% confidence interval (CI) for all NSAIDs as a whole and individually. Eighty-seven studies met the inclusion criteria. Overall, NSAIDs were found to be associated with a statistically significantly increased CVR (RR, 1.24 [95%CI, . The meta-analysis results suggest that the use of the marketed coxibs celecoxib and etoricoxib would be related to a statistically significant CVR increase. Etoricoxib CVR could be higher than that for celecoxib. This increment would be similar to classical NSAID CVR.
In 2015, the drugs used for pain management ranked third in sales worldwide. 1 The expected increase of the global elderly population (22% of the world population in 2050), along with the increased incidence of conditions associated with chronic pain, such as rheumatic diseases and cancer, are expected to cause a steady rise in the consumption of painkillers in general, and particularly nonsteroidal anti-inflammatory drugs (NSAIDs), in future decades. 2 NSAIDs exert their effect by reducing prostaglandin synthesis via the inhibition of the enzyme cyclooxygenase. Classical NSAIDs, such as diclofenac and ibuprofen, have been associated with gastrointestinal adverse effects. 3, 4 In 1999, the 2 first selective cyclooxygenase-2 inhibitors (coxibs) (ie, rofecoxib and celecoxib) were commercialized. They allegedly caused less gastrointestinal toxicity. 5 However, soon after, there was a strong concern that coxibs caused cardiovascular adverse effects. Also, it was suggested that there was a certain cardiovascular risk (CVR) for classical NSAIDs. 6 The VIGOR trial (Vioxx Gastrointestinal Outcomes Research), which compared the gastrointestinal safety of rofecoxib and naproxen, found a 2.38-fold higher risk of cardiovascular events (ie, myocardial infarction, stroke, and cardiovascular death) for rofecoxib. 7 In 2001, the APPROVe trial (Adenomatous Polyp Prevention on Vioxx) evaluated the risk of adenomatous polyps in patients on rofecoxib versus placebo, and results showed a 2-fold higher risk of myocardial infarction for rofecoxib. 8 Following the voluntary withdrawal of rofecoxib by Merck in 2004, a large number of meta-analyses of clinical trials have been published with the aim to elucidate the CVR associated with coxibs other than rofecoxib that are still in the market (ie, celecoxib, etoricoxib, and valdecoxib). The results from these meta-analyses are conflicting. Thus, while Solomon et al 9 found increased CVR for celecoxib, Trelle et al 10 failed to confirm this finding for either celecoxib or etoricoxib. Later, De Vechis et al 11 noted an increased risk for serious cardiovascular events with celecoxib but not with etoricoxib.
Until now, most of the published studies have focused on the analysis of a single cardiovascular event, such as myocardial infarction, 6 ,12 stroke, 13 or atrial fibrillation. 14 We have identified only 2 meta-analyses on NSAIDs' CVR with no restrictions of cardiovascular event terms, and the same author carried out both meta-analyses. 15, 16 Published data suggest that the relative risk (RR) for cardiovascular events associated with NSAIDs may be within the range of 1.0 to 2.0. 15, 17 Thus, due to their excessively small sample size, controlled clinical trials disclose an insufficient number of cardiovascular events, and, consequently, it is hard to identify any differences between individual studies. Currently there is an increasing concern about the CVR associated with NSAIDs. 18, 19 In addition, as mentioned above, only 2 studies on NSAIDs' CVR with no cardiovascular event restrictions were identified. 15, 16 It is our belief that these 3 circumstances are sufficient to justify the conduct of the meta-analysis we present herein.
This study aimed to analyze NSAID-associated CVR in patients >18 years old, including both coxibs and classical NSAIDs, by conducting a meta-analysis of observational studies. The present meta-analysis is compliant with the PRISMA guidelines for systematic reviews (http//www.prisma-statement.org/).
Methods

Search Strategy
A search based on MEDLINE and EMBASE databases covering the period between October 1, 1999, and June 1, 2018, with no language restrictions, was carried out by the authors themselves. Whenever possible, MeSH and Emtrée terms were used for MEDLINE and EMBASE, respectively. The search terms were compiled from terms for the different NSAIDs, the pharmacologic class, the mechanism of action, the cardiovascular events, and the study type. Details on the search strategy are available in supporting information S1. Additionally, a manual search of the references in the selected studies was carried out.
Study Selection
The titles and abstracts of the studies collected from the search were screened. Inclusion criteria were as follows: (1) observational, cohort, or case-control studies;
(2) subjects aged >18 years old on active treatment when the study was carried out; (3) studies providing the RR value, odds ratio, hazard ratio, or incidence rate ratio (IRR), with a 95% confidence interval for any cardiovascular event associated with an individual NSAID or by pharmacologic class; and (4) subjects nonexposed to anti-inflammatory treatment as a control group in the cohort studies, and subjects with no cardiovascular events in the case-control studies.
Studies considered as incomplete, letters, comments, presentations to congresses, case series, unpublished studies, abstracts, and observational studies based on data from randomized clinical trials were all excluded. In addition, we excluded the studies including subjects with cancer, external-use NSAIDs, aspirin prescribed due to its protective effect on cardiovascular morbimortality, or drugs administered intravenously or intramuscularly.
In order to avoid duplicate cases, when 2 studies shared the same database, study period, and measured outcomes, the study with the shortest length was excluded.
Any discrepancies in the selected studies were resolved by consensus among the authors.
Data Collection and Quality of Selected Studies
A standardized data collection form was used to extract the following information from the selected studies: name of the principal author, recruitment year, followup period, publication year, country where the study was conducted, study design, number, age and sex of subjects, baseline CVR, clinical diagnosis, drug under investigation, target cardiovascular event(s), potential confounders that were adjusted for, and risk estimator used in the study and its value with a 95% confidence interval. When the information reported in the study was incomplete, we did not contact the study authors to fill out the form.
Cardiovascular conditions were categorized into cerebrovascular events (stroke, ischemic stroke, hemorrhagic stroke, transient hemorrhagic stroke, intracranial hemorrhage, and subarachnoid hemorrhage); cardiac events (unstable angina, arrhythmia, ischemic heart disease, cardiac event, atrial fibrillation, myocardial infarction, heart failure, cardiac arrest, and acute coronary syndrome); vascular events (lung embolism, deep venous thrombosis, and venous thromboembolism); cardiovascular mortality (cerebrovascular mortality, cardiovascular mortality, myocardial infarction mortality, and sudden death); and other cardiovascular events (results reported as a composite outcome).
The methodological quality of each study was evaluated using the Newcastle-Ottawa Scale (NOS). 20 This scale consists of 3 quality parameters: selection, comparability, and exposure/outcome. The NOS assigns a maximum score of 4, 2, and 3 points for the first, second, and third parameters, respectively. Therefore, a top-quality study would be given a score of 9 points. Studies with a score between 6 and 8 points are considered intermediate-quality studies, and those with a score <6 are regarded as low-quality studies. To increase the homogeneity between the studies included in the meta-analysis, those with a NOS score <4 were excluded.
Statistical Analysis
Data analysis was performed using Review Manager 5.3 software from the Cochrane Collaboration (London, England). We pooled risk values (RR, odds ratio, hazard ratio, and incidence rate ratio) from each selected study using the generic inverse variance method of DerSimonian and Laird. 21 This method assigns a standard deviation-based weight to each study. To increase the power of our estimates, the results from the cohort and case-control studies were combined.
Because cardiovascular events are considered unusual, odds ratios, hazard ratios, and incidence rate ratios were used as estimators of RR in order to carry out statistical calculations. 22 To take into consideration the potential betweenstudies variability resulting from differences in study design, target population, and drugs under investigation, we used a randomized effect model with the aim of obtaining a more conservative result.
We performed 3 independent analyses based on a meta-analytic technique. In the first, NSAIDs were included as a single group. In the second, a difference was made between classical NSAIDs and coxibs, and in the third, each individual drug was included separately. In the 2 first analyses, we included the studies providing results by both pharmacologic class and individual drug. For individual drugs, we analyzed only the results for celecoxib, etoricoxib, rofecoxib, valdecoxib, diclofenac, ibuprofen, and naproxen. Of nonselective NSAIDs, we selected ibuprofen because of its worldwide use, diclofenac because it is considered one of the NSAIDs with the highest CVR, and naproxen because is thought to be one of the NSAIDs with the lowest CVR. 3 When a study presented results by both pharmacologic class and individual drug, precedence was given to the estimation by pharmacologic class.
To identify the dose effect on CVR, a subgroup analysis was performed by including those studies that specifically reported the dose administered to the subjects. Based on the cutoff provided in each study, the doses of the individual NSAIDs were categorized as high and low doses.
Because the subjects' baseline CVR may be a potential confounding factor, we conducted a subgroup analysis with the purpose of quantifying the impact of this factor. To this effect, subjects were classified into 2 baseline CVR groups: (1) low-intermediate risk: a proportion of the subjects participating in the study presented 1 risk factors (ie, hypertension, dyslipidemia, smoking, obesity, or renal failure), but none of them had a history of atherothrombotic disease or diabetes mellitus; and (2) intermediate-high risk: all the subjects participating in the study presented 1 risk factor, and a proportion of them had been diagnosed with atherothrombotic disease or diabetes mellitus.
The statistical heterogeneity of the meta-analysis was assessed by the Cochrane χ 2 test. A high χ 2 value in function of its freedom degrees provides potential evidence for heterogeneity of the intervention effects. Occurrence of statistically significant heterogeneity was considered when P < .05. This test was supplemented with the Higgins I 2 statistics, which provides a quantification of the between-studies variability proportion resulting from heterogeneity but not from randomness. A value ranging between 0% and 25% suggests that the heterogeneity is negligible, between 26% and 50% indicates low heterogeneity, 51% to 75% intermediate heterogeneity, and 76% to 100% high heterogeneity. 23 To check the robustness of results, a sensitivity analysis was performed. The aim of this analysis was to evaluate the individual impact of each study by estimating the pooled RR in the absence of each of the studies. This analysis was supplemented by comparing the obtained results with those resulting from the analysis of the studies with an NOS score >6.
The publication bias was analyzed by the funnel plot visualization and the Egger's regression test. 24 
Results
Characteristics and Quality of the Studies Included
The search strategy yielded 1190 potentially relevant studies ( Figure 1 ). After exclusion of duplicates, 1061 title/abstracts were reviewed. All studies were written in English language, except 2 in the Russian language, which were excluded from the meta-analysis. Of these 1061 abstracts, 170 were selected for full-length article review. After applying inclusion criteria, 87 studies (40 cohort and 47 case-control studies) with more than 27 million participants were selected for the metaanalysis. 12, The detailed characteristics of the selected studies are described in Table 1 .
The most frequently investigated cardiovascular event was myocardial infarction (40 of 87 studies), followed by stroke (34 of 87). Most of the studies included male and female participants. In 4 studies, 34, 41, 107, 108 only females were included.
Mean NOS score of the selected studies was 6, and 39 of 87 studies had an NOS score of 7 or higher. (Table 3) .
Meta-analysis
Heterogeneity Analysis
We investigated the heterogeneity found by means of a subgroup analysis by study design. The pooled CVR of the cohort studies was similar to the case-control studies (RR cohort , 1.25 [1.17-1.33] vs RR case-control , = 1.22 [1.17-1.27]), and coincided with the CVR obtained in the main analysis. Also, although it was not an objective of our study and data were not included in the meta-analysis, we analyzed the selected studies that compared the CVR for coxibs with the CVR for classical NSAIDs, and the direct comparison showed that the risk was higher for coxibs (RR, 1.23 [1.12-1.34]).
Sensitivity Analysis
To confirm the robustness of our results, we performed several sensitivity analyses. First, the pooled RR for cardiovascular events was similar regardless of the study eliminated in each step, with a variation ranging from 1. 20 (1.15-1.25) to 1.24 (1.18-1.30) .
Second, we excluded the selected studies with an NOS score <6 with the intention of conducting a joint analysis of the studies with the best methodological quality. The resulting CVRs did not differ significantly from the CVRs we obtained initially for both the NSAIDs as a pharmacologic class (RR, 1. 
Publication Bias Analysis
The funnel plot used to evaluate the publication bias is provided in Figure 4 . While most of the studies distributed around the funnel apex, the diagram visualization might indicate a slight asymmetry for classical NSAIDs. The Egger regression test for NSAIDs as a pharmacologic class showed a positive slope of the regression line, and the ordinate in the origin was 0.058 (P = .635), which suggests the absence of publication bias.
Discussion
To our knowledge, this is the first meta-analysis of observational studies that includes such a high number of studies (87) and subjects (ie, > 27 million). Two Russian studies were excluded because an adequate translation from Russian into Spanish or English was not available. In addition, the likelihood for these Russian studies to have an impact on the meta-analysis results was thought to be negligible (0.001% of the studies The subgroup analyses by dose revealed a higher CVR for coxibs as compared to classical NSAIDs (Table 3 ). The dose effect for coxibs was noted in earlier meta-analyses. 111 However, it should be highlighted that in our study, a low dose of celecoxib, etoricoxib, ibuprofen, or naproxen did not show a statistically significant CVR. We could not perform the subgroup coxib analyses by subjects' baseline CVR because only 1 study provided information about CVR of coxibs in subjects with low-intermediate baseline CVR (Table 3) .
We decided to identify the CVR for naproxen because most of the earlier meta-analyses indicate that this drug is the NSAID with the lowest CVR. 3, 10, 15, 16, 110 In fact, our results point out that naproxen is one of the NSAIDs with the lowest risk; however, the risk is similar to that of ibuprofen and celecoxib.
In our meta-analysis, valdecoxib is the only coxib that did not present a statistically significant CVR (RR, 1.16 [0.95-1.41]). Interestingly, valdecoxib was withdrawn from the European and North American markets because it was found to be associated with serious skin reactions, such as Stevens-Johnson syndrome, and a considerable risk of cardiovascular events, such as stroke and myocardial infarction. 112 The shortage of studies including valdecoxib in their analyses [27] [28] [29] 89, 90, 98, 99 may be a potential explanation for our conflicting finding.
Our investigation suffers from a number of limitations that are inherent to meta-analyses of observational studies, such as the uncertainty about the quality of each individual study. Nevertheless, the repeated statistical analyses only with the studies with an NOS score >6 yielded results similar to those of the initial analysis. However, it should be borne in mind that the quality of a meta-analysis depends largely on the quality of the original data drawn from the individual studies included therein. Therefore, we could have inadvertently introduced a potential bias in drawing the data from the original studies included in our meta-analysis. It is likely that patients with greater comorbidity (ie, subjects with increased baseline CVR) are treated with coxibs more frequently than those who are healthier; thereby, the treatment itself would act as a confounding factor. However, we feel that our results have not been biased by this potential confounding factor because most of the studies we included reported results adjusted for subjects' comorbidities. In addition, the results from the subgroup analysis based on the baseline CVR showed a high CVR in all the cases (RR low-intermediate , When we started our investigation, rofecoxib had been withdrawn from the world market, and valdecoxib was not available in European or US markets, in both cases due to cardiovascular safety concerns. This may have led to an overestimation of the effect in our results. To check this hypothesis, we repeated the analysis based only on the individual results for celecoxib and etoricoxib. The repeat analysis showed the influence of both rofecoxib and valdecoxib, but the CVR was still statistically significant (RR, 1.13 [1.07-1.20]) .
Most of the studies included in our meta-analysis did not report information on clinical indications and therapy duration, this being another drawback of our investigation. Previously published studies have indicated that dose and duration of therapy have an impact on the CVR. 113 However, it should be kept in mind that some inflammatory diseases, such as rheumatoid arthritis or ankylosing spondylitis, usually present with cardiovascular complications. 114 Only 9 studies in our meta-analysis included patients with rheumatic conditions. 44, 45, 58, 64, 76, 101, 102, 104, 109 Our results showed a statistically significant CVR for these patients (RR, 1.28 [1.20-1.35] ), similar to the increment showed in the main analysis.
The heterogeneity we found in our meta-analysis led us to conduct a specific analysis. In view of the consistency between the results from the main analysis and between those from the analyses of the different subgroups, along with the similarity of the results from the sensitivity analysis, the heterogeneity we found is likely to be related to the broad clinical diversity of patients included in the studies. The high number of selected studies, the broad set of drugs, and the wide variability of patients' comorbidities all may have contributed to the heterogeneity found in this metaanalysis. Likewise, it should be taken into account that χ 2 test has a strong statistical power because it is able to detect small heterogeneities, which are of little clinical significance in meta-analyses including a great number of studies. 22 The funnel plot and the Egger's regression test (P = .044) suggested the existence of slight publication bias related to classical NSAID studies. Consequently, we analyzed this bias based only on the selected studies with the greatest methodological quality (ie, NOS score >6). Our results disclosed that neither the funnel plot (Figure 4 ) nor the Egger's test (P = .423) indicated the existence of the publication bias. Therefore, despite the presence of the publication bias, the similarity between the results from the main analysis and those from the subgroup analysis of NOS score >6 would validate the results of our meta-analysis.
Conclusions
The use of the marketed coxibs celecoxib and etoricoxib are related to a statistically significant CVR increase. Etoricoxib CVR could be higher than that for celecoxib.
This increment is similar to classical NSAID CVR. At low doses, the risk resulting from the combined exposure to NSAIDs, both classical or coxibs, remained statistically significant.
Risk-benefit balance should be assessed for each individual patient when prescribing NSAIDs. A low dose of celecoxib, etoricoxib, ibuprofen, or naproxen should be prescribed when NSAID use is necessary.
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